BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts-Reference-Cited by-同舟云学术

BCR/ABL oncogene-induced PI3K signaling pathway leads to chronic myeloid leukemia pathogenesis by impairing immuno-modulatory function of hemangioblasts

Published:2015-04-03 Issue:5 Volume:22 Page:227-237
ISSN:0929-1903
Container-title:Cancer Gene Therapy
language:en
Short-container-title:Cancer Gene Ther

Author:

Li Q,Wu Y,Fang S,Wang L,Qi H,Zhang Y,Zhang J,Li W

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/cgt201465.pdf

Reference49 articles.

1. Barnes DJ, Melo JV . Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia. Cell Cycle 2006; 5: 2862–2866.

2. Jørgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL . Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+CML cells. Blood 2007; 109: 4016–4019.

3. Jørgensen HG, Copland M, Allan EK, Jiang X, Eaves A, Eaves C et al. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 2006; 12: 626–633.

4. Ries C, Pitsch T, Mentele R, Zahler S, Egea V, Nagase H et al. Identification of a novel 82 kDa proMMP-9 species associated with the surface of leukaemic cells: (auto-)catalytic activation and resistance to inhibition by TIMP-1. Biochem J 2007; 405: 547–558.

5. Yu Q, Stamenkovic I . Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14: 163–176.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. C-Myc inhibition intensified the anti-leukemic properties of Imatinib in chronic myeloid leukemia cells;Molecular Biology Reports;2023-11-04

2. The TKI Era in Chronic Leukemias;Pharmaceutics;2021-12-20

3. The Superior Cytotoxicity of Dual Targeting of BCR/ABL and PI3K in K562 Cells: Proposing a Novel Therapeutic Potential for the Treatment of CML;Indian Journal of Hematology and Blood Transfusion;2021-04-01

4. Identifying Dysregulated lncRNA-Associated ceRNA Network Biomarkers in CML Based on Dynamical Network Biomarkers;BioMed Research International;2020-02-18

5. FAM168A participates in the development of chronic myeloid leukemia via BCR-ABL1/AKT1/NFκB pathway;BMC Cancer;2019-07-10